Analysts Offer Insights on Healthcare Companies: Immunome (IMNM), Sanofi (OtherSNYNF) and MacroGenics (MGNX)
Analyst Ratings on Immunome, Sanofi, and MacroGenics: Analysts from Leerink Partners have maintained bullish ratings on Immunome (Buy, target $38), Sanofi (Buy, target $125.13), and MacroGenics (Buy, target $8), indicating positive sentiment in the healthcare sector despite varying performance metrics among analysts.
Market Consensus and Price Targets: The consensus for Immunome is a Strong Buy with a target of $24.67, while Sanofi has a Moderate Buy rating with an 11.6% upside, and MacroGenics holds a Hold rating with a significant potential upside of 244.8%.
Trade with 70% Backtested Accuracy
Analyst Views on MGNX
About MGNX
About the author
After-Hours Movers: MGNX, SLS, KRMD, HYPR, WVE Experience Significant Changes After Q3 Reports
MacroGenics Earnings Report: MacroGenics, Inc. saw a 10.2% increase in after-hours trading, reporting a third-quarter net income of $16.8 million, down from $56.3 million year-over-year, with revenue falling to $72.8 million.
SELLAS Life Sciences Update: SELLAS Life Sciences Group, Inc. rose 9.4% after narrowing its quarterly net loss to $6.8 million, with cash and equivalents reported at approximately $44.3 million as of September 30, 2025.
KORU Medical Systems Performance: KORU Medical Systems, Inc. gained 8.47% after reporting a narrower net loss of $0.8 million and a 27.2% revenue increase to $10.4 million, while raising its full-year revenue guidance.
Wave Life Sciences Results: Wave Life Sciences Ltd. increased by 5.68% after reporting a third-quarter net loss of $53.9 million, an improvement from the previous year, with revenue of $7.6 million.
MacroGenics Revenue Doubles in Q2
Financial Performance: MacroGenics reported Q2 2025 GAAP revenue of $22.2 million, significantly below the $31.7 million analyst estimate, with a loss per share of $(0.57), missing expectations as well. The company highlighted lower operating costs but faced challenges due to the absence of product sales after exiting its previous marketed product.
Strategic Focus and Pipeline: The company is shifting its focus to research-stage pipeline candidates, emphasizing partnerships and cost management while maintaining sufficient funds through mid-2027. Key upcoming milestones include clinical results for its lead candidate lorigerlimab and potential regulatory approvals for collaborations that could yield significant payments.
